IP Library Granted Patent US 12,448,638
Granted Patent B2
US 12,448,638 · App. 17/931,352 · Granted Oct 21, 2025

Enzyme based system for production of messenger RNA with increased transfection efficiency

Inventors: Brett Morimoto (Culver City, CA); Kayvan Niazi (Culver City, CA); Annie Shin (Culver City, CA); Lise Geissert (Culver City, CA); Philip T. Liu (Culver City, CA)
Assignee: ImmunityBio, Inc.
C12P19/34C12N9/1241C12N9/1247C12Y207/07019
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,448,638
App. No.
17/931,352
Granted
Oct 21, 2025
Kind
B2
Abstract

A method for the production of proteins used in the in vitro transcription (IVT) of messenger RNA (mRNA), wherein the proteins are evaluated for purity and efficacy by the efficiency with which mRNA synthetically derived therefrom, subsequently transfects cells and produces encoded proteins.

Claims (17)

1. A method for in vitro synthesis of mRNA, the method comprising:

transfecting a first plurality of competent bacterial cells with a first plasmid vector comprising an arabinose promoter linked to a nucleic acid sequence encoding T7 RNA polymerase, wherein the first plasmid vector comprises a nucleotide sequence that is at least 95% identical to SEQ ID NO: 19;

transfecting a second plurality of competent bacterial cells with a second plasmid vector comprising at least one arabinose promoter linked to a nucleic acid sequence encoding vaccinia virus capping enzyme (VVCE), wherein the second plasmid vector comprises a nucleotide sequence that is at least 95% identical to SEQ ID NO: 20;

transfecting a third plurality of competent bacterial cells with a third plasmid vector comprising a UUG start codon, an arabinose promoter linked to a nucleic acid sequence encoding polyadenosine (poly (A)) polymerase, wherein the third plasmid vector comprises a nucleotide sequence that is at least 95% identical to SEQ ID NO: 21;

expressing and purifying T7 RNA polymerase from the first plurality of competent bacterial cells;

expressing and purifying VVCE from the second plurality of competent bacterial cells;

expressing and purifying poly (A) polymerase from the third plurality of competent bacterial cells;

adding linearized plasmid DNA to a first composition comprising the purified T7 RNA polymerase to produce RNA transcripts;

adding the RNA transcripts to a second composition comprising the purified VVCE to produce capped RNA transcripts;

adding the capped RNA transcripts to a third composition comprising the purified poly (A) polymerase to produce polyadenylated capped mRNA transcripts; and

purifying mRNA from the third composition.

2. The method of claim 1 , wherein the first plasmid vector comprises a nucleotide sequence that comprises SEQ ID NO: 19.

3. The method of claim 1 , wherein the second plasmid vector comprises a nucleotide sequence that comprises SEQ ID NO: 20.

4. The method of claim 1 , wherein the third plasmid vector comprises a nucleotide sequence that comprises SEQ ID NO: 21.

5. The method of claim 1 , wherein the bacterial competent cells are E. Coli BL21 (DE3) competent cells.

6. The method of claim 1 , wherein VVCE is expressed at 18° C.

7. The method of claim 1 , wherein VVCE is expressed over an 18 hour fermentation period.

Assignments (2)
SECURITY INTEREST Recorded Jan 2, 2024
From: IMMUNITYBIO, INC.; NANTCELL, INC.; RECEPTOME, INC.; VBC HOLDINGS LLC; ALTOR BIOSCIENCE, LLC; ETUBICS CORPORATION; IGDRASOL, INC.
To: INFINITY SA LLC, AS PURCHASER AGENT
Reel/Frame 066179/0074 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 23, 2022
From: MORIMOTO, BRETT; NIAZI, KAYVAN; SHIN, ANNIE; GEISSERT, LISE; LIU, PHILIP T.
To: IMMUNITYBIO, INC.
Reel/Frame 061199/0761 →
Continuity (2)
Provisional Application 63244990 · Sep 16, 2021
Related Publication 20230183770A1 · Jun 15, 2023
References Cited (17)
WO WO2014152027 · 2014 [cited by applicant]
WO WO2020205793 · 2020 [cited by applicant]
WO WO2020243026 · 2020 [cited by applicant]
Cao et al., “Identification of the coding region for a second poly(A) polymerase in [cited by applicant]
Takahashi et al., “Quick and Easy Assembly of a One-Step qRT-PCR Kit for COVID-19 Diagnostics Using In-House Enzymes,” ACS Omega, Mar. 23, 2021, vol. 6(11), pp. 7374-7386. [cited by applicant]
International Search Report and Written Opinion for International (PCT) Patent Application No. PCT/US2022/076290, dated Dec. 27, 2022 11 pages. [cited by applicant]
International Preliminary Report on Patentability for International (PCT) Patent Application No. PCT/US2022/076290, dated Mar. 28, 2024 6 pages. [cited by applicant]
Beck et al., “mRNA therapeutics in cancer immunotherapy,” Molecular Cancer, 2021, vol. 20:69, 24 pages. [cited by applicant]
Cao et al., “Identification of the gene for an [cited by applicant]
Gao et al., “Synthetic modified messenger RNA for terapeutic applications,” Acta Biomaterialia, 2021, retrieved from https://doi.org/10.1016/j.actbio.2021.06.020, 16 pages. [cited by applicant]
Hornblower et al., “Minding your caps and tails,” New England BioLabs, White Paper, (2015), 5 pages. [cited by applicant]
Jackson et al., “The promise of mRNA vaccines: a biotech and industrial perspective,” npj/Vaccines, 2020, vol. 5(11), 6 pages. [cited by applicant]
Ramanathan et al., “Survey and Summary, mRNA capping: biological functions and applications,” Nucleic Acids Research, 2016, vol. 44(16), pp. 7511-7526. [cited by applicant]
Sadarangani et al., “Immunological mechanisms of vaccine-induced protection against COVID-19 in humans,” Progress, Nature Reviews/Immunology, Jul. 1, 2021, 10 pages. [cited by applicant]
Sahin et al., “mRNA-based therapeutics-developing a new class of drugs,” Nature Reviews/Drug Discovery, Oct. 2014, vol. 13, pp. 759-780. [cited by applicant]
Schlake et al., “mRNA as novel technology for passive immunotherapy,” Cellular and Molecular Life Sciences, 2019 (pub online Oct. 17, 2018), vol. 76, pp. 301-328. [cited by applicant]
Wang et al., “mRNA vaccine: a potential therapeutic strategy,” Molecular Cancer, 2021, vol. 20:33, 23 pages. [cited by applicant]